**Clariscan EIRE - Prescribing Information**

**PRESCRIBING INFORMATION CLARISCANTM – gadoteric acid**

*Please refer to full national Summary of Product Characteristics (SmPC) before prescribing. Further information available on request.*

**PRESENTATION**

Clariscan 279.3 mg/ml solution for injection and Solution of injection in pre-filled syringe, containing 279.3 mg/ml gadoteric acid (as gadoterate meglumine) equivalent to 0.5 mmol/mL.

**INDICATIONS**

For diagnostic use, only. Contrast agent for contrast enhancement in MRI for a better visualisation/delineation. Adult and paediatric population (0-18 years): lesions of the brain, spine, and surrounding tissues. Adults and children over 6 months Whole body MRI. Non-coronary angiography in adults only.

**DOSAGE AND METHOD OF ADMINISTRATION**

This medicinal product should only be administered by trained healthcare professionals with technical expertise in performing and interpreting gadolinium enhanced MRI. **MRI of brain and spine: *Adults*:** The recommended dose is 0.1 mmol/kg BW, i.e. 0.2 mL/kg BW. In patients with brain tumours, an additional dose of 0.2 mmol/kg BW, i.e. 0.4 mL/kg BW, may improve tumor characterisation and facilitate therapeutic decision making. ***Children (0-18 years):*** The recommended and maximum dose of Clariscan is 0.1 mmol/kg body weight. Do not use more than one dose during a scan. Careful consideration in neonates up to 4 weeks and infants up to 1 year of age. Lack of information on repeated administration, Clariscan injections should not be repeated before 7 days. **Whole body MRI (including lesions of the liver, kidneys, pancreas, pelvis, lungs, heart, breast, and musculoskeletal system): *Adults and children over 6 months:*** The recommended dose is 0.1 mmol/kg BW, i.e. 0.2 mL/kg BW. **Angiography: *Adults only:*** The recommended dose, IV injection is 0.1 mmol/kg BW, i.e. 0.2 mL/kg BW. **Impaired renal function:** Clariscan should only be used in patients with severe renal impairment (GFR < 30 mL/min/1.73 m2) and in patients in the perioperative liver transplantation period after careful risk/benefit assessment and if the diagnostic

information is essential and not available with non-contrast enhanced MRI If it is necessary to use Clariscan

the dose should not exceed 0.1 mmol/kg body weight. Clariscan injections should not be repeated before 7 days. **Impaired hepatic function:** The adult dose applies. Caution recommended, especially in perioperative liver transplantation period. **Elderly (aged 65 years and above):** No dosage adjustment, but exercise caution.

**CONTRAINDICATIONS**

Hypersensitivity to gadoteric acid, to meglumine or to any medicinal products containing gadolinium.

**WARNINGS AND PRECAUTIONS**

Appropriate facilities should be readily available for any complication, as well as for emergency treatment of severe reaction to the contrast agent (e.g. hypersensitivity, seizures). The usual precaution for MRI examination should be taken. Regarding any metallic object such as exclusion of patients with pacemakers, vascular clips, infusion pumps, nerve stimulators, cochlear implants, or suspected intracorporeal metallic foreign bodies, particularly in the eye. **Not for intrathecal use:** For intravenous injection only. Clariscan

must not be administered by subarachnoid (or epidural) injections. **Extravasation:** In the event of

extravasation local intolerance reactions may be observed, necessitating short term local treatment. **Hypersensitivity reactions:** Hypersensitivity reactions can occur, including life-threatening, and may be either allergic or non-allergic. They can be either immediate (less than 60 minutes), or delayed (up to 7 days). Anaphylactic reactions can occur immediately and can be fatal. Symptoms of an existing asthma may be aggravated. Hypersensitivity reactions can be aggravated in patients on beta-blockers, particularly those with bronchial asthma. These patients may be refractory to standard treatment of hypersensitivity

reactions with beta-agonists. Caution in patients with a history of allergy (e.g. fish and seafood allergy, hay

fever, hives), sensitivity to contrast media and bronchial asthma and premedication with antihistamines and/or glucocorticoids may be considered. Appropriate support measures should be available. **Nephrogenic Systemic Fibrosis (NSF):** Reports of ***NSF*** associated with use of some gadolinium-containing contrast agents in patients with acute or chronic severe renal impairment (GFR < 30 mL/min/1.73 m2). Incidence of acute renal failure is high in patients undergoing liver transplantation. Clariscan should only be

used in patients with severe renal impairment and in patients in the perioperative liver transplantation period after careful risk/benefit assessment and if the diagnostic information is essential and not available with non-contrast enhanced MRI. Prior to administration of Clariscan, it is recommended that all patients are screened for renal dysfunction. **CNS disorders:** Special precaution is necessary in patients with a low threshold for seizures. **Cardiovascular disease:** Clariscan should only be administered after careful benefit

assessment. **Patient preparation:** Nausea and vomiting are known possible undesirable effects when using

MRI contrast agents. The patient should therefore refrain from eating for 2 hours prior to the investigation.

**UNDESIRABLE EFFECTS**

**NSF** [see Warnings and Precautions]  **Clinical Studies Experience: Immune system disorders:**  Uncommon: Hypersensitivity, anaphylactic reaction, anaphylactoid reaction. **Psychiatric disorders:**  Very rare: Agitation, anxiety. **Eye disorders:**  Rare: Conjunctivitis, ocular hyperaemia, vision blurred, lacrimation increased, eyelid oedema. **Nervous system disorders:**  Very common: Paraesthesia, headache. Rare: Dysgeusia. Very rare: Coma, convulsion, syncope, presyncope, dizziness, parosmia, tremor. **Cardiac disorders:**  Very rare: Cardiac arrest, bradycardia, tachycardia, arrhythmia, palpitations. **Respiratory, thoracic and mediastinal disorders:**  Very rare: Respiratory arrest, Rare: Pulmonary oedema, bronchospasm, laryngospasm, pharyngeal oedema, dyspnoea, nasal congestion, sneezing, cough, dry throat. **Gastrointestinal disorders:** Common: Nausea, vomiting. Very rare: Diarrhoea, abdominal pain, salivary hypersecretion. **Skin and subcutaneous system disorders:**  Common: Pruritus, erythema, rash. Rare: Urticaria, hyperhidrosis. Very rare: Eczema, angioedema. Isolated cases of NSF have been reported with gadoteric acid, most of which were in patients co-administered other gadolinium-containing contrast agents. **Vascular disorders:**  Very rare: Hypotension, hypertension, vasodilatation, pallor. **Musculoskeletal and connective tissue disorders:** Very rare: Muscle contracture, muscular weakness, back pain. **General disorders and administration site conditions:**  Common: Feeling hot, feeling cold, injection site. Very rare: Chest discomfort, fever, chills, face oedema, asthenia, injection site discomfort, back pain, malaise, thoracic pain, superficial phlebitis, decreased oxygen saturation. Injection site reaction, injection site oedema, injection site extravasation, injection site inflammation (in case of extravasation), injection site necrosis (in case of extravas ation). See full SmPC for adverse reactions reported with other intravenous MRI contrast agents.

**Post marketing experience:** The most commonly reported adverse reactions following administration are nausea, vomiting, pruritus and hypersensitivity reactions. The most frequently observed hypersensitivity

reactions are localised, extended or generalised skin reactions which most often occur immediately (during the injection or within one hour after the start of injection) or sometimes delayed (one hour to several days after injection). Immediate reactions include one or more effects, which appear simultaneously or sequentially, which are most often cutaneous, respiratory and/or cardiovascular reactions. Each sign may be a warning sign of a starting shock and go very rarely to death.

**DRUG INTERACTIONS**

No formal studies. No interactions with other medicinal products have been observed. Beta-blockers, vasoactive substances, angiotensin-converting enzyme inhibitors, angiotensin receptor antagonists: These medicinal products induce decreased efficacy of cardiovascular compensation mechanisms of blood pressure. Contrast media may increase the incidence of hypersensitivity reactions in patients taking beta- blockers.

**PREGNANCY AND LACTATION**

No data in pregnant women. Clariscan should not be used during pregnancy unless the clinical condition of the woman requires use of gadoteric acid. **Nursing Mothers** At clinical doses, no effects on the infant are anticipated due to the small amount excreted in milk and poor absorption from the gut. Continuing or discontinuing breast feeding for a period of 24 hours after administration, should be at the discretion of the doctor and lactating mother. **Fertility:** no clinical data.

**SPECIAL POPULATIONS**

**Neonates and infants:** Clariscan should only be used in neonates up to 4 weeks of age and infants up to 1 year age after careful consideration. **Elderly (aged 65 years and above):** Patients should be screened due to age related decline in renal function.

**OVERDOSE**

Clariscan can be removed by haemodialysis. However, there is no evidence that haemodialysis is suitable for prevention of NSF.

**EFFECTS ON THE ABILITY TO DRIVE AND USE MACHINES**

No studies. Ambulant patients while driving vehicles or operating machinery should take into account that nausea may incidentally occur.

**INSTRUCTIONS FOR USE AND HANDLING**

For single use. The solution for injection should be inspected visually prior to use. Only clear solutions free of visible particles should be used. In neonates and infants, the required dose should be administered by hand. The peel-off tracking label on the syringes/vials/bottles should be stuck onto the patient record. The dose used should also be recorded. See SmPC for full instructions.

**MARKETING AUTHORISATION HOLDER**

GE Healthcare AS, Nycoveien 1-2, 4220 Nydalen, NO-0401 OSLO, NORWAY

**MARKETING AUTHORISATION HOLDER**

PA0735/011/001 and PA0735/011/002

**CLASSIFICATION FOR SUPPLY**

Subject to medical prescription

**DATE OF REVISION OF THE TEXT**

February 2018

**Reporting suspected adverse reactions is important. Any suspected adverse reactions should be reported to:**

**HPRA Pharmacovigilance**

**Earlsfort Terrace**

**IRL - Dublin 2**

**Tel: +353 1 6764971**

**Fax: +353 1 6762517**

**Website: www.hpra.ie**

**e-mail:** [**medsafety@hpra.ie**](mailto:medsafety@hpra.ie)**.**